HBV-related hepatocellular carcinoma
Conditions
Interventions
Control group:conventional western treatment
therapy group:Ershu Jiedu Decoction Granules on the basis of conventional western treatment
Sponsors
Shuguang Hospital affiliated with Shanghai University of TCM
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Patients who met the western and Traditional Chinese diagnostic criteria for hepatitis B associated liver cancer, were unable to accept surgery, TACE and ablation, and were unable to tolerate or unwilling to accept palliative first-line (sorafenib, renvaritinib) and second-line (regolfinib) system treatment. ?(2) Aged between 18 and 70, male or female. ?(3) China liver cancer staging (CNLC) was stage IIIa, IIIb or IV. ?(4) Karnofsky Performance Scale (KPS) score =60. ?(5) Child-Pugh score of liver function =9. ?(6) Estimated survival =3 months. ?(7) Patients and their families are willing to cooperate with follow-up. ?(8) Agree to participate in the project and sign the informed consent.
Exclusion criteria
Exclusion criteria: (1) Pregnant or lactating women. (2) Patients with obvious coagulation mechanism disorder and bleeding tendency. (3) patients with serious heart, brain, lung and other important organ diseases or serious complications (complicated with hepatic encephalopathy, refractory ascites, hepatorenal syndrome etc.) or with systemic severe infection. (4) Currently participating in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| lab indication;Quality of life;Safety index;liver imageological examination;the syndrome of traditional chinese medicine; | — |
Countries
China
Contacts
Public ContactYang Cheng
Outcome results
None listed